CV Safety Gets Diabetes Drugs Approved, Not Sold, AstraZeneca Exec Notes

Firms shouldn't lose sight of the need to build the commercial aspects of their type 2 diabetes drugs as they focus on reorienting clinical trials to include cardiovascular risk assessment, according to an AstraZeneca exec